"Metastatic head" trang 1 - tải miễn phí từ tailieunhanh
Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
15    77    1
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial

Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial
10    57    1
Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma

Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
10    1    1
Rationale and design of LUX-Head & Neck 1: A randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

Rationale and design of LUX-Head & Neck 1: A randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy
9    74    1
The head and neck in surgical pathology (Volume 2 - Second edition): Part 2

The head and neck in surgical pathology (Volume 2 - Second edition): Part 2
422    59    0
Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: Realworld data in Korea

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: Realworld data in Korea
9    45    1
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: A randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen

Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: A randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen
10    61    1
An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: Successive lines of active chemotherapeutic agents

An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: Successive lines of active chemotherapeutic agents
8    36    2
Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer

Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer
11    33    1
Real-world study of the impact of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) on quality of life and productivity in Europe

Real-world study of the impact of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) on quality of life and productivity in Europe
12    26    1
Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: A phase I trial

Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: A phase I trial
10    21    2
Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: A retrospective study

Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: A retrospective study
6    1    1
Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: A real-world data analysis

Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: A real-world data analysis
9    1    1
Metachronous immune-related adverse events involving type 1 diabetes and isolated adrenocorticotropic hormone deficiency associated with pembrolizumab monotherapy for metastatic head and neck cancer: A case report

Metachronous immune-related adverse events involving type 1 diabetes and isolated adrenocorticotropic hormone deficiency associated with pembrolizumab monotherapy for metastatic head and neck cancer: A case report
6    15    1
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer

A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer
15    8    1
Metastatic squamous cell carcinoma from primary hypopharynx source to gastric mucosa presenting as massive gastrointestinal bleeding

Metastatic squamous cell carcinoma from primary hypopharynx source to gastric mucosa presenting as massive gastrointestinal bleeding
5    6    2